Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma

To determine the maximum tolerated dose (MTD) of pemetrexed and carboplatin given in combination, to derive a recommended dose for phase II studies, and to explore its efficacy. We assessed toxicities and explored the activity of the drug combination exclusively in patients with malignant pleural me...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 20; no. 16; p. 3533
Main Authors:	Hughes, Andy, Calvert, Paula, Azzabi, Ashraf, Plummer, Ruth, Johnson, Rob, Rusthoven, Jim, Griffin, Melanie, Fishwick, Kevin, Boddy, Alan V, Verrill, Mark, Calvert, Hilary
Format:	Journal Article
Language:	English
Published:	United States 15.08.2002
Subjects:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Area Under Curve Carboplatin - administration & dosage Dose-Response Relationship, Drug Female Glutamates - administration & dosage Guanine - administration & dosage Guanine - analogs & derivatives Hematologic Diseases - chemically induced Humans Male Maximum Tolerated Dose Mesothelioma - drug therapy Mesothelioma - mortality Middle Aged Pemetrexed Pleural Neoplasms - drug therapy Pleural Neoplasms - mortality Survival Rate
ISSN:	0732-183X
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!